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Hepatitis Awareness Month and 
Testing Day, May 2018
The United States commemorates National Hepatitis 
Awareness Month each May, and May 19 is designated 
as Hepatitis Testing Day. Viral hepatitis still persists as a 
major public health threat despite availability of preven-
tive measures such as vaccines and therapies, including a 
curative treatment for hepatitis C virus (HCV) infection.
New cases of hepatitis B virus (HBV) and HCV infections 
are on the rise, largely among persons who inject drugs, 
with some attributed to the current U.S. opioid epidemic 
(1). Recent hepatitis A outbreaks have also occurred among 
unvaccinated injection drug users and homeless persons 
(2). Since August 2016, CDC has responded to hepatitis A 
outbreaks with high HBV/HCV co-infection, hospitaliza-
tion, and mortality rates in multiple states (https://www.cdc.
gov/hepatitis/outbreaks/2017March-HepatitisA.htm). New 
cases of perinatal HBV infection also continue (1); recently, 
CDC updated recommendations to strengthen vaccination 
among newborns and manage pregnant women (3).
This issue of MMWR includes an article about the 
promising outcomes of three HBV programs that imple-
mented community-based services to improve HBV test-
ing, linkage to care, and treatment among persons born 
in intermediate-high prevalence countries (4).
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Among an estimated 850,000 to 2.2 million persons with 
chronic hepatitis B virus (HBV) infection in the United States, 
70% are non–U.S.-born (1,2). All patients require linkage to care, 
and approximately 20%–40% require antiviral treatment (3). 
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Without treatment, one in four persons chronically infected 
with HBV will die prematurely from liver failure, liver cirrhosis, 
or hepatocellular carcinoma (4). To mitigate morbidity and 
mortality, CDC funded a cooperative agreement to develop 
hepatitis B testing and linkage-to-care programs serving non–
U.S.-born persons during October 2014–September 2017. 
This report describes each program’s operational services and 
partnerships with primary care centers, community-based 
organizations, and public health departments to recruit non–
U.S.-born persons for HBV testing using the hepatitis B surface 
antigen (HBsAg) and link those whose test results were positive 
to HBV-directed care (medical visit attendance with monitor-
ing of HBV DNA and liver enzyme tests). Among 10,152 pro-
gram participants, 757 (7.5%) were HBsAg-positive, indicative 
of chronic HBV infection; among these, 643 (85%) attended 
≥1 medical visit, 587 (78%) received HBV-directed care, and 
137 (18%) were prescribed antiviral treatment. Among 273 
household contacts of HBsAg-positive persons, 39 (14%) 
had positive test results for HBsAg. Prevalence of current 
HBV infection was high in this non–U.S.-born population 
and among household and sexual contacts of HBV-infected 
persons. HBV testing and linkage to care can be achieved 
through partnerships with community organizations, health 
centers, and public health departments.
HBV testing and linkage-to-care programs serving 
non–U.S.-born populations were located at a nongovernmen-
tal agency in Chicago, Illinois; community health centers in 
Livingston, New Jersey and New York City, New York; and an 
academic health center in Sacramento, California. Programs 
partnered with community-based organizations (CBOs), 
medical clinics (federally qualified health centers, primary care/
specialists) and public health departments to implement vari-
ous community-based services (Supplementary Table; https://
stacks.cdc.gov/view/cdc/53787). Programs performed HBV 
screening by testing for HBsAg; persons whose test results 
were positive received a second HBsAg test 6 months later to 
confirm chronic HBV infection. Testing for antibody (total or 
immunoglobulin G [IgG]) to hepatitis B core antigen (anti-HBc) 
and antibody to hepatitis B surface antigen (anti-HBs) was per-
formed when feasible. Linkage to care was defined as documen-
tation of at least one medical visit. Community-based services 
used to facilitate linkage to care were qualitatively assessed and 
included community screening events, clinical decision support 
tools in the electronic medical record (EMR), including flagging 
of charts of patients who were potentially at high risk for infec-
tion, provider education and feedback, and patient navigation, 
which was defined as individualized efforts to assist patients in 
accessing health care services (5).
Two programs (Chicago and Livingston/New York City) 
participated in HBV testing and vaccination of household 
contacts of persons who tested positive for HBsAg. These 
household contacts were offered HBV testing, and those whose 
test results were HBsAG-positive were linked to care; persons 
whose test results were HBsAG-negative with positive anti-
HBs results (indicative of immunity through immunization 
or resolved infection) were reassured; and persons whose test 
Morbidity and Mortality Weekly Report
MMWR / May 18, 2018 / Vol. 67 / No. 19 543US Department of Health and Human Services/Centers for Disease Control and Prevention
results were negative for all three HBV seromarkers (susceptible 
to infection) were offered hepatitis B vaccination (3-dose series 
over 6 months). 
Among persons whose test results were positive for HBsAg, 
demographic characteristics, including sex, year of birth, race/
ethnicity, health insurance status, and country of birth were 
collected, as were HBV-specific linkage-to-care indicators, 
including documentation of two medical visits (retention in 
care), and HBV-directed care, including monitoring HBV 
DNA, alanine aminotransferase, and hepatitis B e antigen 
(engaged in care). Information on diagnosis of hepatocellular 
carcinoma and liver cirrhosis was collected. Risk factor data 
were collected through voluntary questionnaires. A descriptive 
analysis was performed, and odds ratios with 95% confidence 
intervals were calculated using logistic regression.
Among 10,152 program participants, 757 (7.5%) had test 
results that were positive for HBsAg, indicating the presence 
of chronic HBV infection. The median age of these patients 
was 40 years (interquartile range 32–53 years); 344 (45%) 
were female, 602 (80%) were Asian, and 122 (16%) were black 
(Table). The most frequently reported countries of origin of 
participants were China (32%), Vietnam (16%), Myanmar 
(8%), Taiwan (7%), and Laos (3%). Among the 757 per-
sons whose test results were positive for HBsAg, 634 (84%) 
attended ≥1 medical visit, 587 (78%) received HBV-directed 
care, 430 (57%) attended ≥2 medical visits, and 137 (18%) 
were prescribed antiviral therapy (Figure). Among HBsAg-
positive participants, 123 (22%) were not linked to care, either 
because they received care in a different health system or were 
lost to follow-up. Nine (1.2%) persons received a diagnosis of 
hepatocellular carcinoma, and liver cirrhosis was diagnosed in 
17 (2.2%). Among 8,837 participants who received anti-HBc 
testing, 2,832 (32%) tested positive, and among 7,421 tested 
for anti-HBs, 4,284 (58%) tested positive.
All three programs implemented community screening 
events, patient navigation, and EMR strategies. Chicago 
developed a patient navigation program; Livingston/New 
York City implemented a provider education and feedback 
curriculum; and Sacramento used the EMR to flag patients by 
Asian surname for HBV testing and to link HBsAg-positive 
patients identified in the EMR to care management to facilitate 
linkage to care.
HBsAg-positive persons who had health insurance were 
more likely to receive HBV-directed care than were those who 
were uninsured (Table). Antiviral treatment was more likely 
to be prescribed for those HBsAg-positive persons who were 
men, aged >50 years, who had liver cirrhosis or hepatocellular 
carcinoma, or who had a family history of HBV infection or 
hepatocellular carcinoma (Table).
Among 273 household contacts of HBsAg-positive partici-
pants, 39 (14%) had positive test results for HBsAg, 83 (30%) 
had negative test results for HBsAg and positive results for anti-
HBc (immune because of resolved infection), and 101 (37%) 
were anti-HBs-positive and anti-HBc-negative (immune 
because of vaccination). Fifty (18%) household contacts had 
negative test results for all three HBV seromarkers, indicat-
ing susceptibility; among these persons, 1, 2, and 3 doses of 
hepatitis B vaccine were received by the end of the project by 
37 (74%), 32 (64%), and 25 (50%) participants, respectively.
Discussion
In this analysis of community-based services used by three 
HBV testing and linkage-to-care programs that implement 
CDC’s HBV testing recommendations (6) and link persons 
with chronic HBV infection to care, the overall prevalence of 
HBV infection among participants was 7.5%. Services used 
to link 78% of patients to HBV-directed care included com-
munity screening events, patient navigation, use of the EMR, 
and provider education and feedback. A 14% HBV infection 
rate was observed among household contacts of persons with 
HBV infection.
HBV testing and linkage to care was accomplished through 
targeted public health interventions, including partnerships 
with public health, CBOs, and health centers. Chicago 
developed partnerships with 11 CBOs, two health centers 
(a network of federally qualified health centers and a refugee 
health center), and two public health departments; each site 
implemented a clinic-based patient navigation program to 
facilitate access to care for persons with HBV infection. The 
Livingston/New York City program held HBV testing events 
in collaboration with community partners, local health depart-
ments, and its hospital; the program reported that combining 
community screening events with general health fairs led to 
more persons receiving HBV screening. Livingston developed a 
free HBV testing coupon for testing at the affiliated laboratory; 
HBsAg-positive patients received care at a primary care center 
(Livingston) and a federally qualified health center (New York 
City). Clinics offered trainings in HBV testing and linkage 
to care, followed by provider feedback to assess performance. 
Partnerships with local health departments improved HBV 
case reporting and contact testing. The program in Sacramento 
implemented community services, including HBV testing 
events at health fairs and faith-based centers; HBsAg-positive 
persons with insurance received HBV care within the health 
system, and those without insurance received care at student-
run clinics.
EMR strategies have previously been documented to increase 
HBV testing rates (7); the program in Chicago included EMR 
prompts to identify populations at high risk, the program 
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TABLE. Percentage of HBsAg-positive persons participating in three programs to increase hepatitis B testing and linkage to care are who 
received HBV-directed care* and treatment, by demographic characteristics — Sacramento, California; Livingston, New Jersey and New York 
City, New York; and Chicago, Illinois, October 2014–September 2017
Demographic characteristic
HBsAg–positive Received HBV–directed care* Prescribed antiviral
No. (% of total) No. (%) Unadjusted OR (95% CI) No. (%) Unadjusted OR (95% CI)
Total 757 (100) 587 (78) N/A 137 (18) N/A
Sex
Female 344 (45) 276 (80) Referent 50 (15) Referent
Male 413 (55) 349 (85) 1.3 (0.9–1.8) 87 (21) 1.6 (1.1–2.4)
Age group (yrs)
<50 518 (68) 423 (82) Referent 83 (16) Referent
>50 239 (32) 164 (69) 0.5 (0.3–0.7) 54 (23) 2.0 (1.4–3.0)
Race
White 17 (2) 14 (82) Referent 2 (12) Referent
Black/African 122 (16) 83 (68) 0.5 (0.1–1.7) 7 (6) 2.3 (0.5–10.4)
Asian 602 (80) 474 (79) 0.8 (0.2–2.8) 122 (20) 0.5 (0.1–2.4)
Native American/Pacific Islander 3 (0) 3 (100) —† 1 (33) 3.8 (0.2–62.8)
Other/Unknown 13 (2) 13 (100) —† 5 (38) —†
Health insurance
None 121 (16) 68 (56) 0.3 (0.2–0.4) 19 (16) 0.9 (0.5–1.7)
Private 210 (28) 174 (83) Referent 41 (20) Referent
Public 334 (44) 289 (87) 1.3 (0.8–2.1) 56 (17) 0.8 (0.5–1.3)
Missing 92 (12) 56 (61) N/A 21 (23) N/A
Primary language
English 229 (30) 178 (78) 1.0 (0.7–1.4) 52 (23) 1.4 (0.9–2.0)
Not English (yes to any other language) 520 (69) 406 (78) Referent 84 (16) Referent
Missing 8 (1) 3 (38) N/A 1 (13) N/A
Country of origin
U.S.-born 16 (2) 13 (81) 1.3 (0.4–4.5) 3 (19) 1.2 (0.3–4.3)
Non–U.S.-born 732 (97) 567 (77) Referent 133 (18) Referent
Missing 9 (1) 7 (78) N/A 1 (11) N/A
Liver disease
Cirrhosis (vs. no cirrhosis) 18 (2) 17 (94) 1.3 (0.1–9.9) 14 (78) 13.1 (4.2–40.6)
HCC (vs. no HCC) 9 (1) 9 (100) —† 7 (78) 24.6 (3.0–202.4)
Neither cirrhosis nor HCC 469 (62) 439 (94) N/A 98 (21) N/A
Missing 264 (35) 128 (48) N/A 24 (9) N/A
Family history
Family history of HBV (vs. no family history of HBV) 190 (25) 158 (83) 1.1 (0.7–1.7) 45 (24) 1.7 (1.1–2.7)
Family history of HCC (vs. no family history of HCC) 66 (9) 53 (80) 0.9 (0.5–1.7) 20 (30) 2.2 (1.2–4.0)
No family history of HBV/HCC 364 (48) 303 (83) N/A 59 (16) N/A
Missing 182 (24) 111 (61) N/A 29 (16) N/A
Risk factors (other than non–U.S.-born)
No risk factors reported 485 (64) 409 (84) Referent 82 (17) Referent
At least one risk factor§ reported 139 (18) 124 (89) 1.5 (0.9–2.8) 37 (27) 1.8 (1.1–2.7)
No risk factor data available 133 (18) 54 (41) N/A 18 (14) N/A
Abbreviations: CI = confidence interval; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; N/A = not applicable; 
OR = odds ratio.
* Received testing for hepatitis B e antigen, hepatitis B virus DNA, and alanine transaminase.
† Insufficient cell size to calculate OR.
§ Injection drug use, men who have sex with men, household contact, sexual contact, multiple sex partners, human immunodeficiency virus–positive.  
in Livingston modified their EMR to include HBV testing 
order sets (clinical decision support tools that include labora-
tory tests recommended for evaluating patients with chronic 
HBV infection), and the program in Sacramento developed an 
algorithm to flag charts of Asian persons to recommend testing 
as well as monthly EMR querying of HBsAg-positive patients 
to identify those not currently in care. A critical linkage-to-
care strategy was the use of patient navigators at all sites (5,8). 
Patient navigators received training about HBV disease effects, 
cultural competency, insurance evaluation, the marketplace 
insurance application process, development of bilingual edu-
cation materials, and scheduling medical appointments and 
patients’ guidance through health systems (5).
An estimated 20%–40% of HBsAg-positive persons require 
antiviral treatment (3), and this initiative demonstrated that 18% 
of identified HBsAg-positive patients received antiviral treatment. 
Reasons for not treating might include cost, access to care, patient 
preferences, or variation in clinical guidelines used (9,10).
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FIGURE. Hepatitis B linkage-to-care continuum* — three U.S. programs, October 2014–September 2017
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Abbreviation: HBsAg = hepatitis B surface antigen.
* Stages in care continuum are the following: linked to care = attended ≥1 medical visit; engaged in care = received hepatitis B e antigen, hepatitis B virus DNA, and 
alanine transaminase testing; retained in care = attended ≥2 medical visits; prescribed antiviral = given hepatitis B antiviral treatment (approximately 20%-40% of 
patients with chronic hepatitis B virus infection require treatment).
Summary
What is already known about this topic?
Among the 850,000 to 2.2 million U.S. residents with chronic 
hepatitis B virus (HBV) infection, approximately 70% are 
non–U.S.-born; nearly two thirds are unaware of their infection 
status, and <30% are linked to care and treatment.
What is added by this report?
CDC funded three programs to develop hepatitis B testing and 
linkage-to-care programs serving non–U.S.-born persons during 
2014–2017; 78% of persons with chronic HBV infection were linked 
to care using community-based services. HBV infection rate among 
household contacts of HBsAg-positive persons was 14%.
What are the implications for public health practice?
HBV testing and linkage to care can be achieved among 
hard-to-reach populations through partnerships with community 
organizations, health centers, and public health departments.
The 14% HBV infection rate among household contacts in 
this population is higher than the 0.3% reported in the gen-
eral population (2), highlighting the importance of screening 
household contacts of persons with HBV infection. Persons 
who are not immune are at risk for infection, and in these 
programs, 74% of susceptible household contacts received at 
least 1 dose of hepatitis B vaccine.
The findings in this report are subject to at least four 
limitations. First, each program used services specific to their 
catchment population, which limits generalizability. Second, 
linkage-to-care indicators might be underestimated because 
some participants had pending appointments that were not 
included at the end of the project period. Third, ascertainment 
of factors associated with progression in the care continuum 
is limited because of missing data (not all characteristics were 
documented). Finally, the proportion of treatment-eligible 
persons determined by clinical guidelines was not assessed.
HBV testing and linkage to care can be achieved among hard-
to-reach populations through partnerships with community 
organizations, health centers, and public health departments. 
Household and sexual contacts of HBV-infected persons 
should be tested and linked to care.
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